Connect your AI

Arcus Biosciences RCUS Contract Liabilities

Contract Liabilities at other companies

Kymera TherapeuticsKYMR

$0—

ExelixisEXEL

——

Other financials

Income statement

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arcus Biosciences's contract liabilities?: Arcus Biosciences (RCUS) reported contract liabilities of $79M in Q1 2026.
How has Arcus Biosciences's contract liabilities changed year-over-year?: Arcus Biosciences's contract liabilities decreased by 72.9% year-over-year, from $291M to $79M.
What is the long-term trend for Arcus Biosciences's contract liabilities?: Over 2 years (2023 to 2025), Arcus Biosciences's contract liabilities has grown at a -55.7% compound annual growth rate (CAGR), from $398M to $78M.
What does contract liabilities mean?: Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.